Usted buscó: angiomyolipom (Danés - Inglés)

angiomyolipom-responsrate1,2 – %
angiomyolipoma response rate1,2

renal angiomyolipom forbundet med tsc
renal angiomyolipoma associated with tsc

renal angiomyolipom i tilknytning til tsc
renal angiomyolipoma associated with tsc

bedste overordnede angiomyolipom-respons – %
best overall angiomyolipoma response

patienter med renal angiomyolipom forbundet med tsc:
patients with renal angiomyolipoma associated with tsc:

tabel 4 exist-2 - angiomyolipom-respons
table 4 exist-2 - angiomyolipoma response

renal angiomyolipom i tilknytning til tuberøst sklerosekompleks (tsc)
renal angiomyolipoma associated with tuberous sclerosis complex (tsc)

2 angiomyolipom-respons blev bekræftet med en yderligere scanning.
2 angiomyolipoma responses were confirmed with a repeat scan.

progression af angiomyolipom blev observeret hos 14,3 % af patienterne.
angiomyolipoma progressions were observed in 14.3% of the patients.

ved den endelige analyse var mediantiden til progression af angiomyolipom ikke nået.
at the final analysis, median time to angiomyolipoma progression was not reached.

hos patienter med renal angiomyolipom er den anbefalede dosis 10 mg én gang dagligt.
in patients with renal angiomyolipoma, the recommended dose is 10 mg once a day.

de estimerede progressionsfrie rater for angiomyolipom efter 24 måneder og 48 måneder var hhv.
the estimated angiomyolipoma progression-free rates at 24 months and 48 months were 91.6% and 83.1%, respectively.

det primære endepunkt for virkning var responsraten på angiomyolipom baseret på en uafhængig central radiologisk gennemgang.
the primary efficacy endpoint was angiomyolipoma response rate based on independent central radiology review.

for patienter med renal angiomyolipom forbundet med tsc: hvis en patient har brug for samtidig behandling med potente
for patients with renal angiomyolipoma associated with tsc:

hvis du får votubia til behandling af tsc med angiomyolipom i nyrerne, er den normale, daglige dosis 10 mg.
if you receive votubia for the treatment of tsc with angiomyolipoma of the kidney, the usual dose is 10 mg, to be taken once daily.

hos patienter med renal angiomyolipom og svært nedsat leverfunktion anbefales votubia kun, såfremt den ønskede fordel opvejer risiciene.
for patients with renal angiomyolipoma and severe impairment of liver function votubia is only recommended if the desired benefit outweighs the risk.

hvis du behandles for tsc med angiomyolipom i nyrerne, ordineres votubia kun til dig af en læge med erfaring i behandling af patienter med tsc.
if you are being treated for tsc with angiomyolipoma of the kidney, votubia will only be prescribed for you by a doctor with experience in treating patients with tsc.

votubia må ikke bruges til børn og teenagere med tsc, som har angiomyolipom i nyrerne, men ikke sega, da det ikke er blevet undersøgt hos denne patientgruppe.
votubia is not to be used in children or adolescents with tsc who have angiomyolipoma of the kidney in the absence of sega, as it has not been studied in such patients.

det var tilladt, at patienter, der initialt blev behandlet med placebo, krydsede over til everolimus ved tidspunktet for progression af angiomyolipom og ved erkendelse af, at behandling med everolimus var overlegen i forhold til placebo.
patients initially treated with placebo were allowed to cross over to everolimus at the time of angiomyolipoma progression and upon recognition that treatment with everolimus was superior to treatment with placebo.

af de deltagende patienter havde 83,1 % angiomyolipom ≥4 cm (28,8 % ≥8 cm), 78,0 % havde bilateral angiomyolipom, og 39,0 % havde tidligere fået foretaget renal embolisering/nefrektomi; 96,6 % havde hudlæsioner ved baseline, og 44,1 % havde mål-sega’er (mindst en sega ≥1 cm for den længste diameter).
of the enrolled patients, 83.1% had angiomyolipomas ≥4 cm (28.8% ≥8 cm), 78.0% had bilateral angiomyolipomas, and 39.0% had undergone prior renal embolisation/nephrectomy; 96.6% had skin lesions at baseline and 44.1% had target segas (at least one sega ≥1 cm in longest diameter).